Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 5, 2017

Primary Completion Date

March 13, 2018

Study Completion Date

March 13, 2018

Conditions
Malar and Sub-malar Volume Deficiency
Interventions
DEVICE

Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)

"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."

Trial Locations (1)

20900

DERMING, Milan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Derming SRL

OTHER